Omics-based biomarkers: current status and potential use in the clinic

In recent years, the use of high-throughput omics technologies has led to the rapid discovery of many candidate biomarkers. However, few of them have made the transition to the clinic. In this review, the promise of omics technologies to contribute to the process of biomarker development is describe...

Full description

Bibliographic Details
Main Authors: Héctor Quezada, Ana Laura Guzmán-Ortiz, Hugo Díaz-Sánchez, Ricardo Valle-Rios, Jesús Aguirre-Hernández
Format: Article
Language:English
Published: Permanyer 2017-05-01
Series:Boletín Médico del Hospital Infantil de México
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1665114617300680
id doaj-038215ac985346c2b69f6145e76dab71
record_format Article
spelling doaj-038215ac985346c2b69f6145e76dab712021-04-02T13:59:54ZengPermanyerBoletín Médico del Hospital Infantil de México1665-11462017-05-0174321922610.1016/j.bmhimx.2017.03.003Omics-based biomarkers: current status and potential use in the clinicHéctor Quezada0Ana Laura Guzmán-Ortiz1Hugo Díaz-Sánchez2Ricardo Valle-Rios3Jesús Aguirre-Hernández4Laboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, MexicoLaboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, MexicoLaboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, MexicoLaboratorio de Investigación en Inmunología y Proteómica, Hospital Infantil de México Federico Gómez, Mexico City, MexicoLaboratorio de Genómica, Genética y Bioinformática, Hospital Infantil de México Federico Gómez, Mexico City, MexicoIn recent years, the use of high-throughput omics technologies has led to the rapid discovery of many candidate biomarkers. However, few of them have made the transition to the clinic. In this review, the promise of omics technologies to contribute to the process of biomarker development is described. An overview of the current state in this area is presented with examples of genomics, proteomics, transcriptomics, metabolomics and microbiomics biomarkers in the field of oncology, along with some proposed strategies to accelerate their validation and translation to improve the care of patients with neoplasms. The inherent complexity underlying neoplasms combined with the requirement of developing well-designed biomarker discovery processes based on omics technologies present a challenge for the effective development of biomarkers that may be useful in guiding therapies, addressing disease risks, and predicting clinical outcomes.http://www.sciencedirect.com/science/article/pii/S1665114617300680BiomarkerGenomicsProteomicsMetabolomics
collection DOAJ
language English
format Article
sources DOAJ
author Héctor Quezada
Ana Laura Guzmán-Ortiz
Hugo Díaz-Sánchez
Ricardo Valle-Rios
Jesús Aguirre-Hernández
spellingShingle Héctor Quezada
Ana Laura Guzmán-Ortiz
Hugo Díaz-Sánchez
Ricardo Valle-Rios
Jesús Aguirre-Hernández
Omics-based biomarkers: current status and potential use in the clinic
Boletín Médico del Hospital Infantil de México
Biomarker
Genomics
Proteomics
Metabolomics
author_facet Héctor Quezada
Ana Laura Guzmán-Ortiz
Hugo Díaz-Sánchez
Ricardo Valle-Rios
Jesús Aguirre-Hernández
author_sort Héctor Quezada
title Omics-based biomarkers: current status and potential use in the clinic
title_short Omics-based biomarkers: current status and potential use in the clinic
title_full Omics-based biomarkers: current status and potential use in the clinic
title_fullStr Omics-based biomarkers: current status and potential use in the clinic
title_full_unstemmed Omics-based biomarkers: current status and potential use in the clinic
title_sort omics-based biomarkers: current status and potential use in the clinic
publisher Permanyer
series Boletín Médico del Hospital Infantil de México
issn 1665-1146
publishDate 2017-05-01
description In recent years, the use of high-throughput omics technologies has led to the rapid discovery of many candidate biomarkers. However, few of them have made the transition to the clinic. In this review, the promise of omics technologies to contribute to the process of biomarker development is described. An overview of the current state in this area is presented with examples of genomics, proteomics, transcriptomics, metabolomics and microbiomics biomarkers in the field of oncology, along with some proposed strategies to accelerate their validation and translation to improve the care of patients with neoplasms. The inherent complexity underlying neoplasms combined with the requirement of developing well-designed biomarker discovery processes based on omics technologies present a challenge for the effective development of biomarkers that may be useful in guiding therapies, addressing disease risks, and predicting clinical outcomes.
topic Biomarker
Genomics
Proteomics
Metabolomics
url http://www.sciencedirect.com/science/article/pii/S1665114617300680
work_keys_str_mv AT hectorquezada omicsbasedbiomarkerscurrentstatusandpotentialuseintheclinic
AT analauraguzmanortiz omicsbasedbiomarkerscurrentstatusandpotentialuseintheclinic
AT hugodiazsanchez omicsbasedbiomarkerscurrentstatusandpotentialuseintheclinic
AT ricardovallerios omicsbasedbiomarkerscurrentstatusandpotentialuseintheclinic
AT jesusaguirrehernandez omicsbasedbiomarkerscurrentstatusandpotentialuseintheclinic
_version_ 1721563342163673088